The hexavalent meningococcal vaccine HexaMen, containing six PorAs on two vesicles, was tested in clinical studies. Although fourfold increases in serum bactericidal activity (SBA) titers against all of the PorAs were observed, there were significant differences between PorA-specific SBA titers. SBA titers were mainly directed against one PorA from each vesicle, P1.5-2,10 and P1.5-1,2-2, and were lower against the other PorAs, especially P1.7-2,4 and P1.19,15-1. We investigated whether these differences were due to immunological interference that resulted in competition between the three PorAs on the same vesicle or whether they were caused by a difference in the immunogenicities of the separate PorAs. Therefore, mice were immunized either with HexaMen, with six monovalent outer membrane vesicles (OMVs) representing the same six PorAs simultaneously (HexaMix), or with only one of the monovalent OMVs. The immunoglobulin G and SBA titers after HexaMen immunization in mice resembled the results obtained in clinical studies. Although immunization with HexaMix gave higher titers than immunization with HexaMen for some PorAs, the pattern of high and low titers was the same. Similar differences in immunogenicity between subtypes were seen after monovalent immunization when interference was eliminated as a cause of the differences. Monovalent immunization resulted in higher titers for P1.5-1,2-2 and P1.7,16 than immunization with HexaMen. However, no significant differences were found for the weakly immunogenic PorAs, P1.7-2,4 and P1.19,15-1. Since immunization with the six PorAs in the trivalent presentation form (HexaMen) and in the mixture of monovalent vesicles (HexaMix) resulted in the same pattern of high and low titers, we concluded that the differences between the PorA-specific responses are due to differences in the immunogenicities of the various PorAs and not due to interference that results in competition between different PorAs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC219571PMC
http://dx.doi.org/10.1128/IAI.71.11.6367-6371.2003DOI Listing

Publication Analysis

Top Keywords

sba titers
16
poras
11
presentation form
8
hexamen poras
8
clinical studies
8
titers
8
differences pora-specific
8
poras p17-24
8
p17-24 p11915-1
8
interference competition
8

Similar Publications

As robust cellular responses are important for protection against dengue, this phase 2 study evaluated the kinetics and phenotype of T cell responses induced by TAK-003, a live-attenuated tetravalent dengue vaccine, in 4-16-year-old living in dengue-endemic countries (NCT02948829). Two hundred participants received TAK-003 on Days 1 and 90. Interferon-gamma (IFN-γ) enzyme-linked immunospot assay [ELISPOT] and intracellular cytokine staining were used to analyze T cell response and functionality, using peptide pools representing non-structural (NS) proteins NS3 and NS5 matching DENV-1, -2, -3, and -4 and DENV-2 NS1.

View Article and Find Full Text PDF
Article Synopsis
  • There is a need for more affordable and effective vaccines to prevent bacterial meningitis caused by serogroup B globally.
  • The study explores the use of modified outer membrane vesicles (mOMVs) from commensal bacteria to elicit immune responses against meningococcal antigens, specifically various versions of factor H binding protein, Heparin Binding Antigen, and Adhesin A.
  • The results showed that mice immunized with these engineered mOMVs produced antibodies to all targeted antigens and demonstrated significant serum bactericidal activity, indicating the potential of mOMVs for developing a protective vaccine against meningococcal disease.
View Article and Find Full Text PDF
Article Synopsis
  • * This study explored two vaccine candidates, cNHBA and MetQ, aiming to enhance their immune response by creating fusions with MetQ protein fragments, using aluminium hydroxide as an adjuvant for better vaccine production and efficacy.
  • * Results showed that these fusions triggered strong immune responses in mice, leading to significant bacterial killing and a reduction in bacterial adherence, identifying MetQ-cNHBA and cNHBA-Met2 as the most promising candidates for future vaccine development against gonorr
View Article and Find Full Text PDF
Article Synopsis
  • There are two vaccines available to prevent serogroup B meningococcal disease: 4CMenB, which is part of routine infant immunizations, and MenB-fHbp.
  • Immunogenicity data indicates that while protective antibody levels initially rise after vaccination, they decline over time, with a booster dose helping to restore levels initially.
  • Current evidence suggests that a booster for adolescents who were vaccinated in infancy may not provide long-lasting protection, and revaccination might be necessary instead.
View Article and Find Full Text PDF

Background: Brucellosis vaccines are designed to induce cellular immunity. An effective brucellosis vaccine could induce both cellular and humoral immunity. Serum Bactericidal Assay (SBA) is an important method for determining vaccine humoral immunity.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!